Literature DB >> 21883437

Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes.

P Bowman1, T J McDonald, B M Shields, B A Knight, A T Hattersley.   

Abstract

AIMS: Serum C-peptide can be used in Type 2 diabetes as a measure of endogenous insulin secretion, but practicalities of collection limit its routine clinical use. Urine C-peptide creatinine ratio is a non-invasive alternative that is stable for at least 3 days at room temperature in boric acid preservative. We aimed to assess the utility of urine C-peptide creatinine ratio in individuals with Type 2 diabetes as an alternative to serum C-peptide.
METHODS: We assessed, in 77 individuals with Type 2 diabetes, the reproducibility of, and correlations between, fasting and postprandial urine C-peptide creatinine ratio and serum C-peptide, and the impact of renal impairment (estimated glomerular filtration rate < 60 ml min(-1) 1.73 m(-2)) on these correlations.
RESULTS: Urine C-peptide creatinine ratio was at least as reproducible as serum C-peptide [fasting coefficient of variation mean (95% CI): 28 (21-35)% vs. 38 (26-59)% and 2-h post-meal 26 (18-33)% vs. 27 (20-34)%. Urine C-peptide creatinine ratio 2 h post-meal was correlated with stimulated serum C-peptide, both the 2-h value (r = 0.64, P < 0.001) and the 2-h area under the C-peptide curve (r = 0.63, P < 0.001). The association seen was similar in patients with and without moderate renal impairment (P = 0.6).
CONCLUSIONS: In patients with Type 2 diabetes, a single urine C-peptide creatinine ratio is a stable, reproducible measure that is well correlated with serum C-peptide following meal stimulation, even if there is moderate renal impairment. Urine C-peptide creatinine ratio therefore has potential for use in clinical practice in the assessment of Type 2 diabetes.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21883437     DOI: 10.1111/j.1464-5491.2011.03428.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Capturing residual beta cell function in type 1 diabetes.

Authors:  Flemming Pociot
Journal:  Diabetologia       Date:  2018-11-03       Impact factor: 10.122

2.  Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.

Authors:  S V Hope; B A Knight; B M Shields; A T Hattersley; T J McDonald; A G Jones
Journal:  Diabet Med       Date:  2016-05-26       Impact factor: 4.359

3.  Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.

Authors:  Richard A Oram; Timothy J McDonald; Beverley M Shields; Michelle M Hudson; Maggie H Shepherd; Suzanne Hammersley; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2014-12-17       Impact factor: 19.112

Review 4.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

5.  Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study.

Authors:  Richard A Oram; Andrew Rawlingson; Beverley M Shields; Coralie Bingham; Rachel E J Besser; Tim J McDonald; Bridget A Knight; Andrew T Hattersley
Journal:  BMJ Open       Date:  2013-12-18       Impact factor: 2.692

6.  Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis.

Authors:  Suzy V Hope; Sophie Wienand-Barnett; Maggie Shepherd; Sophie M King; Charles Fox; Kamlesh Khunti; Richard A Oram; Bea A Knight; Andrew T Hattersley; Angus G Jones; Beverley M Shields
Journal:  Br J Gen Pract       Date:  2016-04-14       Impact factor: 5.386

7.  Effects of a Follow-On Formula Containing Isomaltulose (Palatinose™) on Metabolic Response, Acceptance, Tolerance and Safety in Infants: A Randomized-Controlled Trial.

Authors:  M Fleddermann; A Rauh-Pfeiffer; H Demmelmair; L Holdt; D Teupser; B Koletzko
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 8.  A Practical Review of C-Peptide Testing in Diabetes.

Authors:  Emma Leighton; Christopher Ar Sainsbury; Gregory C Jones
Journal:  Diabetes Ther       Date:  2017-05-08       Impact factor: 2.945

Review 9.  Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes.

Authors:  Yoshifumi Saisho
Journal:  Int J Mol Sci       Date:  2016-05-17       Impact factor: 5.923

10.  Post-glucose-load urinary C-peptide and glucose concentration obtained during OGTT do not affect oral minimal model-based plasma indices.

Authors:  Sjaam Jainandunsing; J L Darcos Wattimena; Trinet Rietveld; Joram N I van Miert; Eric J G Sijbrands; Felix W M de Rooij
Journal:  Endocrine       Date:  2015-11-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.